Strategic Partnership OmniSeq has a history of collaborating with major academic and medical centers (UPMC, UPMC Hamot) and operates within a network that includes Roswell Park Cancer Institute. This presents a sales opportunity to position advanced molecular profiling and RNA sequencing for immunotherapy selection within large systems and ongoing clinical trials.

Immuno-Oncology Focus The company states significant investments to improve diagnostics for immuno-oncology therapy selection and has launched immune-related assays (Immune Report Card). This signals demand for products that guide IO treatment choices, enabling a revenue path by targeting pharma partnerships and trial sites.

Clinical Assay Portfolio OmniSeq offers clinically available assays like OmniSeq Comprehensive and Immune Report Card that interrogate genomic and immune markers tied to approved therapies and trials. There is an opportunity to upsell to expand adoption across hospitals, cancer centers, and community clinics seeking comprehensive profiling.

Acquisition & Integration LabCorp acquired OmniSeq in 2021, indicating a path to leverage broader distribution, scale, and integrated services. Sales motion can target LabCorp customers or leverage LabCorp’s sales force to cross-sell OmniSeq offerings and new IO-focused diagnostics.

Growth Signposts With modest revenue in the $10–25M range and a lean staff, there is potential for rapid expansion through new contract trials, expanded EU/US reimbursement pathways, and additional sequencing-based assays. Focus sales on expanding market reach, pharma collaborations, and regulatory-ready assays to accelerate adoption.